New hope for Drug-Resistant TB: shorter, All-Pill treatment under study
NCT ID NCT03828201
First seen Apr 15, 2026 · Last updated May 24, 2026 · Updated 7 times
Summary
This study tests a combination of five oral drugs (bedaquiline, delamanid, levofloxacin, linezolid, and clofazimine) for treating multidrug-resistant tuberculosis (MDR-TB). The goal is to see if a shorter, all-pill regimen can effectively cure the infection. About 271 people with MDR-TB will receive the treatment for 16, 24, 32, or 40 weeks to find the best duration.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS, MULTIDRUG-RESISTANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
De La Salle Health Sciences Institute
Dasmariñas, 4114, Philippines
-
National Lung Hospital
Hanoi, Vietnam
Conditions
Explore the condition pages connected to this study.